Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MLTX MoonLake Immunotherapeutics	$54.88 -1.4%	$49.33	$31.42 ▼ $58.26	$3.51B	1.27	478,573 shs	269,235 shs
PTGX Protagonist Therapeutics	$54.99 -3.1%	$54.05	$33.31 ▼ $60.60	$3.42B	2.33	941,345 shs	614,116 shs
SRRK Scholar Rock	$32.29 +1.0%	$35.83	$6.76 ▼ $46.98	$3.10B	0.48	1.22 million shs	963,130 shs
ZYME Zymeworks	$14.30 +2.6%	$12.99	$9.03 ▼ $17.70	$1.07B	1.26	535,622 shs	543,046 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MLTX MoonLake Immunotherapeutics	+1.48%	+5.48%	+9.42%	+47.77%	+22.79%
PTGX Protagonist Therapeutics	+4.02%	+5.39%	+2.70%	+27.72%	+40.71%
SRRK Scholar Rock	-0.68%	-7.63%	-17.13%	+3.73%	+229.35%
ZYME Zymeworks	+7.07%	+12.33%	+4.42%	+20.90%	+36.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MLTX MoonLake Immunotherapeutics	2.5609 of 5 stars	4.4	1.0	0.0	1.6	2.5	0.0
PTGX Protagonist Therapeutics	1.9238 of 5 stars	2.5	3.0	0.0	3.2	2.5	0.0
SRRK Scholar Rock	4.3967 of 5 stars	4.6	0.0	4.4	1.6	3.3	0.6
ZYME Zymeworks	3.2392 of 5 stars	3.5	4.0	0.0	3.0	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MLTX MoonLake Immunotherapeutics	2.78	Moderate Buy	$74.43	35.62% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$67.20	22.20% Upside
SRRK Scholar Rock	3.22	Buy	$45.14	39.80% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.43	49.85% Upside

Current Analyst Ratings Breakdown

Latest ZYME, SRRK, PTGX, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$19.00 ➝ $22.00
8/7/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	PTGX Protagonist Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$67.00 ➝ $69.00
8/7/2025	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $45.00
8/6/2025	MLTX MoonLake Immunotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$74.00 ➝ $82.00
7/30/2025	SRRK Scholar Rock	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Strong-Buy	$53.00
7/28/2025	MLTX MoonLake Immunotherapeutics	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/28/2025	MLTX MoonLake Immunotherapeutics	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$65.00
7/17/2025	SRRK Scholar Rock	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
7/3/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$13.00
6/18/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$5.59 per share	N/A
PTGX Protagonist Therapeutics	$434.43M	7.87	$4.56 per share	12.07	$10.74 per share	5.12
SRRK Scholar Rock	$33.19M	93.52	N/A	N/A	$2.43 per share	13.29
ZYME Zymeworks	$122.87M	8.75	N/A	N/A	$6.63 per share	2.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.78	N/A	N/A	N/A	N/A	-40.98%	-35.81%	N/A
PTGX Protagonist Therapeutics	$275.19M	$0.70	78.56	N/A	N/A	24.88%	8.12%	7.41%	N/A
SRRK Scholar Rock	-$246.29M	-$2.91	N/A	N/A	N/A	N/A	-127.11%	-90.09%	N/A
ZYME Zymeworks	-$118.67M	-$0.97	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	10/30/2025 (Estimated)

Latest ZYME, SRRK, PTGX, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	N/A	ZYME Zymeworks	-$0.52	$0.03	+$0.55	N/A	$17.18 million	$48.73 million
8/6/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	-$0.55	-$0.02	-$0.55	$8.32 million	$5.55 million
8/6/2025	Q2 2025	SRRK Scholar Rock	-$0.66	-$0.98	-$0.32	-$0.98	$0.11 million	N/A
8/5/2025	Q2 2025	MLTX MoonLake Immunotherapeutics	-$0.73	-$0.87	-$0.14	-$0.87	N/A	N/A
5/14/2025	Q1 2025	SRRK Scholar Rock	-$0.63	-$0.67	-$0.04	-$0.67	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MLTX MoonLake Immunotherapeutics	0.21	16.65	16.65
PTGX Protagonist Therapeutics	N/A	16.97	16.97
SRRK Scholar Rock	0.21	6.33	6.33
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MLTX MoonLake Immunotherapeutics	93.85%
PTGX Protagonist Therapeutics	98.63%
SRRK Scholar Rock	91.08%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
MLTX MoonLake Immunotherapeutics	12.02%
PTGX Protagonist Therapeutics	4.90%
SRRK Scholar Rock	13.30%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.32 million	Optionable
PTGX Protagonist Therapeutics	120	62.21 million	59.16 million	Optionable
SRRK Scholar Rock	140	96.13 million	83.34 million	Optionable
ZYME Zymeworks	460	75.17 million	67.56 million	Optionable

ZYME, SRRK, PTGX, and MLTX Headlines

Recent News About These Companies

Zymeworks Earnings Call: Revenue Surge and Strategic Gains

August 13 at 2:54 AM | msn.com

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

August 12 at 10:55 AM | zacks.com

Citigroup Raises Zymeworks (NYSE:ZYME) Price Target to $22.00

August 12 at 9:47 AM | marketbeat.com

Citigroup Increases Zymeworks (NYSE:ZYME) Price Target to $22.00

August 12 at 4:04 AM | americanbankingnews.com

Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital

August 12 at 3:38 AM | marketbeat.com

Zymeworks Inc.: Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11 at 8:16 PM | finanznachrichten.de

Zymeworks Strengthens Leadership with New Board Appointments

August 11 at 6:40 AM | tipranks.com

Zymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of Directors

August 11 at 6:19 AM | quiverquant.comQ

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11 at 6:19 AM | financialpost.comF

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11 at 6:00 AM | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from Analysts

August 11 at 2:15 AM | marketbeat.com

Earnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

August 10, 2025 | finance.yahoo.com

Zymeworks Inc. (NYSE:ZYME) Given Consensus Rating of "Moderate Buy" by Analysts

August 10, 2025 | americanbankingnews.com

Zymeworks (NYSE:ZYME) Announces Earnings Results, Beats Expectations By $0.55 EPS

August 9, 2025 | marketbeat.com

Zymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progression

August 8, 2025 | msn.com

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

August 7, 2025 | zacks.com

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Zymeworks (ZYME) Projected to Post Earnings on Thursday

July 31, 2025 | marketbeat.com

Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and ...

July 30, 2025 | finance.yahoo.com

FDA Greenlights Trials of Novel ADC and Radiopharmaceutical in Solid Tumors

July 30, 2025 | targetedonc.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME, SRRK, PTGX, and MLTX Company Descriptions

MoonLake Immunotherapeutics NASDAQ:MLTX

$54.88 -0.77 (-1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$54.78 -0.10 (-0.18%)

As of 04:10 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Protagonist Therapeutics NASDAQ:PTGX

$54.99 -1.73 (-3.05%)

Closing price 04:00 PM Eastern

Extended Trading

$54.97 -0.02 (-0.04%)

As of 04:20 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Scholar Rock NASDAQ:SRRK

$32.29 +0.31 (+0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$32.30 +0.01 (+0.02%)

As of 04:20 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Zymeworks NYSE:ZYME

$14.30 +0.36 (+2.58%)

Closing price 04:00 PM Eastern

Extended Trading

$14.30 +0.00 (+0.03%)

As of 04:20 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time